Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients
Author:
Publisher
Ferrata Storti Foundation (Haematologica)
Subject
Hematology
Reference17 articles.
1. Bruno B, Wäsch R, Engelhardt M. European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma. Haematologica. 2021; 106(8):2054-2065.
2. Gagelmann N, Riecken K, Wolschke C. Development of CAR-T cell therapies for multiple myeloma. Leukemia. 2020; 34(9):2317-2332.
3. Munshi NC, Anderson LD, Shah N. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021; 384(8):705-716.
4. Berdeja JG, Madduri D, Usmani SZ. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021; 398(10297):314-324.
5. Gagelmann N, Ayuk F, Atanackovic D, Kröger N. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: a meta-analysis. Eur J Haematol. 2020; 104(4):318-327.
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma;Blood Advances;2024-07-31
2. Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma;Blood Advances;2024-07-24
3. Fast and furious: Changing gears on the road to cure with chimeric antigen receptor T cells in multiple myeloma;Seminars in Hematology;2024-07
4. Improving Access to T-Cell Therapies in Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-07
5. A research center’s experience of T-cell–redirecting therapies in triple-class refractory multiple myeloma;Blood Advances;2024-06-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3